Cancer Capital CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
10-Q: Cancer Capital Corp. Reports Third Quarter 2024 Results, Continues Search for Merger Opportunity
Cancer Capital Corp. reports a net loss of $8,436 for the third quarter of 2024 and continues to seek a merger or acquisition target.
Cancer Capital Corp.'s Q2 2024 filing reveals ongoing losses, minimal cash reserves, and continued reliance on related-party funding, raising substantial doubt about its ability to continue as a going concern.
Cancer Capital Corp. reported no revenue and a net loss of $15,939 for the quarter ended March 31, 2024, with substantial doubt about its ability to continue as a going concern.